User:Mr. Ibrahem/Flotufolastat F-18
Clinical data | |
---|---|
Trade names | Posluma |
Other names | 18F-rhPSMA-7.3 |
License data | |
Routes of administration | Intravenous |
Drug class | Radioactive diagnostic agent |
Legal status | |
Legal status | |
Chemical and physical data | |
3D model (JSmol) | |
| |
|
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent used in positron emission tomography (PET) imaging of prostate cancer.[1] Specifically it is used in prostate-specific membrane antigen (PSMA) positive disease to look for spread or recurrence.[1] It is given by injection into a vein.[1]
Common side effects include diarrhea, high blood pressure, and pain at the site of injection.[1] Other side effects include exposure to radiation.[1] The active ingredient is flotufolastat F-18 gallium.[1]
Flotufolastat F-18 was approved for medical use in the United States in 2023.[1]